Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)

López‐Medrano, Francisco; Alfayate, Santiago; Carratalà, Jordi; Chamorro-Camazón, Judith; Cordero, Elisa; Cruz-Cañete, Marta; Fernández-Prada, María; García-Cenoz, Manuel; Marcos, María Ángeles; Melón, Santiago; Moreno-Millán, Nemesio; García, María Dolorès Vivero; Lejarazu, Raúl Ortíz de; Pérez‐Martín, Jaime Jesús; Rodríguez‐García, Juan; Schwarz‐Chavarri, Germán; Tagarro-García, Alfredo; Esso-Arbolave, Diego van; Viasus, Diego; Pumarola, Tomás

doi:10.1016/j.eimce.2022.10.013

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination among the immunocompromised of the above target population should be done with inactivated influenza vaccines (IIV). For adults for whose age group the vaccine is licensed, a quadrivalent vaccine containing two strains of type A influenza virus (H1N1pdm09 and H3N2) and two of influenza B type (Victoria and Yamagata lineages), either adjuvanted, high-dose antigen, or recombinant, are recommended [149,150]. At the time of writing this article, WHO has not included, for the first time, a strain of influenza B virus of the Yamagata lineage in the annual composition of influenza vaccines for the Southern Hemisphere [151].…”

Section: Active Immunoprophylaxis With Approved Viral Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review

Candel,

Salavert,

Basaras

et al. 2023

JCM

View full text Add to dashboard Cite

Community-acquired pneumonia represents the third-highest cause of mortality in industrialized countries and the first due to infection. Although guidelines for the approach to this infection model are widely implemented in international health schemes, information continually emerges that generates controversy or requires updating its management. This paper reviews the most important issues in the approach to this process, such as an aetiologic update using new molecular platforms or imaging techniques, including the diagnostic stewardship in different clinical settings. It also reviews both the Intensive Care Unit admission criteria and those of clinical stability to discharge. An update in antibiotic, in oxygen, or steroidal therapy is presented. It also analyzes the management out-of-hospital in CAP requiring hospitalization, the main factors for readmission, and an approach to therapeutic failure or rescue. Finally, the main strategies for prevention and vaccination in both immunocompetent and immunocompromised hosts are reviewed.

show abstract

Section: Active Immunoprophylaxis With Approved Viral Vaccinesmentioning

confidence: 99%

“…Influenza vaccine should be administered in October-November for those living in the Northern Hemisphere. Vaccination is indicated until the end of the annual influenza season for those who did not receive the vaccine in October-November [149,150].…”

Section: Active Immunoprophylaxis With Approved Viral Vaccinesmentioning

confidence: 99%